Oryzon Genomics Announces Listing on Madrid Stock Exchange
Oryzon to Ring the Madrid Stock Exchange Opening Bell in Celebration of IPO on Monday, December 14
• Company valued at approximately EUR 100 million
• Priced at EUR 3.39 per share
• Founders, Carlos Buesa and Tamara Maes, control 26.3% of shares outstanding
BARCELONA, SPAIN and CAMBRIDGE MA.
Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, today announced that the National Securities Market Commission (CNMV) has approved the listing of Oryzon’s shares on the Madrid Stock Exchange. Oryzon will begin trading on December 14, 2015 under the stock symbol ORY (ISIN Code: ES0167733015). The shares will be priced at EUR 3.39 per share, resulting in a market capitalization of EUR 96.5 million.